Plain-English translation of NCT06235931 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a combination of three medications—Darcilil, Pyrrotinib, and an aromatase inhibitor—can work well together to treat advanced breast cancer that is triple-positive (meaning it has three specific markers that make it respond to these drugs). The research will look at whether this three-drug combination is both safe and effective for older adults with this type of cancer.
Triple-positive breast cancer is a specific type that has not been studied much in older patients. Doctors want to know if combining these three medications together can help control the disease better than treatments used today, and whether older adults can tolerate this combination safely.
You likely qualify if…
You likely don't qualify if…
You will receive the three-medication combination as your treatment, visiting the research center regularly (about every 4 weeks) for check-ups, blood tests, and imaging scans to measure how well the treatment is working. You will continue this treatment until your cancer progresses, side effects become too difficult to manage, or your doctor decides to stop. The study includes follow-up visits after treatment ends to check your health and monitor for any long-term effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China